Sep 15, 2021 / 01:30PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Well, great. Good morning, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Johnson & Johnson with us for this session.
Before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So pleased to have the team with us from J&J. I am going to turn it over to Joe Wolk, the CFO, who's going to make some opening comments, and then we'll jump into Q&A.
Joseph J. Wolk - Johnson & Johnson - Executive VP & CFO
Matthew, certainly a pleasure to be here to represent Johnson & Johnson. I'm pleased to be joined by our R&D colleague in the Pharmaceutical segment, Mathai Mammen, who I'm sure you'll engage with on some questions.
Just
Johnson & Johnson at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers